| Autor: |
Barrea, Luigi, Verde, Ludovica, Grant, William B., Frias-Toral, Evelyn, Sarno, Gerardo, Vetrani, Claudia, Ceriani, Florencia, Garcia-Velasquez, Eloisa, Contreras-Briceño, José, Savastano, Silvia, Colao, Annamaria, Muscogiuri, Giovanna |
| Zdroj: |
Nutrients; Apr2022, Vol. 14 Issue 8, pN.PAG-N.PAG, 15p |
| Abstrakt: |
Coronavirus disease 2019 (COVID-19) has quickly become a global pandemic. Reports from different parts of the world indicate that a significant proportion of people who have recovered from COVID-19 are suffering from various health problems collectively referred to as "long COVID-19". Common symptoms include fatigue, shortness of breath, cough, joint pain, chest pain, muscle aches, headaches, and so on. Vitamin D is an immunomodulatory hormone with proven efficacy against various upper respiratory tract infections. Vitamin D can inhibit hyperinflammatory reactions and accelerate the healing process in the affected areas, especially in lung tissue. Moreover, vitamin D deficiency has been associated with the severity and mortality of COVID-19 cases, with a high prevalence of hypovitaminosis D found in patients with COVID-19 and acute respiratory failure. Thus, there are promising reasons to promote research into the effects of vitamin D supplementation in COVID-19 patients. However, no studies to date have found that vitamin D affects post-COVID-19 symptoms or biomarkers. Based on this scenario, this review aims to provide an up-to-date overview of the potential role of vitamin D in long COVID-19 and of the current literature on this topic. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
